Advanced Search

Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine 2003 December;47(4) > The Quarterly Journal of Nuclear Medicine 2003 December;47(4):256-69

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUETHE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A Journal on Nuclear Medicine and Molecular Imaging

A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413

Frequency: Quarterly

ISSN 1824-4785

Online ISSN 1827-1936

 

The Quarterly Journal of Nuclear Medicine 2003 December;47(4):256-69

USE OF RADIOLABELLED PEPTIDES FOR SCINTIGRAPHY IN NON-ONCOLOGIC DISEASES 

The developing role of peptide radiopharmaceuticals in the study of chronic inflammation: new techniques for novel therapeutic options

Chianelli M. 1, Parisella M. G. 2, D’Alessandra C. 2, Corsetti F. 2, Scopinaro F. 2, Signore A. 2

1 Nuclear Medicine Unit Regina Apostolorum Hospital, Albano, Rome, Italy
2 Nuclear Medicine 2nd Faculty of Mecicine, University La Sapienza, Rome, Italy

Chronic inflam­ma­to­ry dis­eas­es usu­al­ly ­lead to fibro­sis of the tar­get ­organ and con­se­quent ­hypo func­tion. They are ­often relaps­ing, inval­i­dat­ing and ­require ­life-­long treat­ment. In ­this ­class of ­patients it is ­very impor­tant to try and ­achieve spe­cif­ic ­immune sup­pres­sion to extin­guish the ­immune pro­cess ­with the aim of pre­vent­ing the dis­ease, pre­vent­ing or delay­ing com­pli­ca­tions and avoid­ing dis­ease ­relapse, ­often requir­ing sur­gi­cal inter­ven­tion. It is impor­tant ­that, ­while attempt­ing to ­improve the qual­ity of ­life of ­these ­patients by ­means of ­anti-inflam­ma­to­ry ­drugs, ­side ­effects are ­reduced to a min­i­mum via the use of spe­cif­ic ­immune ther­a­pies ­that ­block as selec­tive­ly as pos­sible the path­o­log­ic mech­a­nism respon­sible for the dis­ease. New ther­a­peu­tic ­options are ­being devel­oped for spe­cif­ic tar­get­ed ther­a­pies. Several ­trials are ­being per­formed to ­assess the effi­ca­cy and safe­ty of ­this ­approach. All of ­them, how­ev­er, ­rely on the clin­i­cal assess­ment of the ­patients to eval­u­ate the ­effect of treat­ment. It ­would be impor­tant to use an objec­tive and reli­able meth­od to high­light direct­ly the ­immune pro­cess under­ly­ing the indi­vid­u­al dis­ease. This man­u­script ­reviews the radio­phar­ma­ceu­ti­cals avail­able or recent­ly devel­oped for imag­ing chron­ic inflam­ma­to­ry dis­eas­es and ­their use for ther­a­py deci­sion mak­ing and fol­low-up.

language: English


FULL TEXT  REPRINTS

top of page